trial

A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)

NCTId NCT01192867
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 629 (actual)
Sponsored by Hoffmann-La Roche
Primary completion 2014-05-26
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
629 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2010-12-11
Primary completion
2014-05-26
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
RO4917838

Sponsors

Hoffmann-La RocheLead Sponsor

Sites

122 total
Little Rock, United StatesAnaheim, United StatesCerritos, United StatesDowney, United StatesLa Palma, United StatesPasadena, United StatesPico Rivera, United StatesMiami, United StatesMarietta, United StatesOak Brook, United StatesIowa City, United StatesGlen Burnie, United States

Linked catalysts

1
A Study of RO4917838 in Participants With Persistent, Predominant Negative Sympt — primary completion2014-05-26

Facts & assertions

4 sourced
Enrollment
629
Phase
PHASE3
Primary Completion Date
2014-05-26
Status
COMPLETED
relationships
The graph out of here
drug
RO4917838
drug
lead_sponsor
Hoffmann-La Roche
company
indication
Schizophrenia
indication
Schizophrenia
indication